Tag: epirubicin

News

02/15/12

Grapes might help protect against Adriamycin-induced heart damage

12/07/11

Modern chemotherapy reduces BC death by about a third

10/09/11

Low white blood cell count may indicate chemotherapy is working

12/10/10

Adding zoledronic acid to chemotherapy does not improve markers

Studies

• Statin use is associated with a lower risk of mortality in patients with malignant breast cancer treated with anthracyclines. A global federated health database analysis Cite
  Bucci T, Gue Y, Dobson R, Palmieri C, Pignatelli P, Cross M, et al. Statin use is associated with a lower risk of mortality in patients with malignant breast cancer treated with anthracyclines. A global federated health database analysis. European Heart Journal. Oxford University Press (OUP); 2023; 44 10.1093/eurheartj/ehad655.2876
• Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer Cite
  Wang Y, Ronckers CM, van Leeuwen FE, Moskowitz CS, Leisenring W, Armstrong GT, et al. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nature Medicine. Springer Science and Business Media LLC; 2023; 29:2268-2277 10.1038/s41591-023-02514-1
• Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients Cite
  Balaji S, Antony AK, Tonchev H, Scichilone G, Morsy M, Deen H, et al. Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients. Biomedicines. MDPI AG; 2023; 11:2286 10.3390/biomedicines11082286
• Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010 Cite
  Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. JAMA Network Open. American Medical Association (AMA); 2023; 6:e2254669 10.1001/jamanetworkopen.2022.54669
• Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study Cite
  Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.01736
• Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy Cite
  Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, et al. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy. JAMA Oncology. American Medical Association (AMA); 2021; 7:1544 10.1001/jamaoncol.2021.3395
• A careful reassessment of anthracycline use in curable breast cancer Cite
  Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, et al. A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00342-5
• Focal white matter microstructural alteration after anthracycline-based systemic treatment in long-term breast cancer survivors: a structural magnetic resonance imaging study Cite
  Zhang H, Li P, Liu T, Wang X, Feng W, Chen R, et al. Focal white matter microstructural alteration after anthracycline-based systemic treatment in long-term breast cancer survivors: a structural magnetic resonance imaging study. Brain Imaging and Behavior. Springer Science and Business Media LLC; 2021; 10.1007/s11682-021-00551-3
• Interactions of Some Chemotherapeutic Agents as Epirubicin, Gemcitabine and Paclitaxel in Multicomponent Systems Based on Orange Essential Oil Cite
  Samide A, Tutunaru B, Varut R, Oprea B, Iordache S. Interactions of Some Chemotherapeutic Agents as Epirubicin, Gemcitabine and Paclitaxel in Multicomponent Systems Based on Orange Essential Oil. Pharmaceuticals. MDPI AG; 2021; 14:619 10.3390/ph14070619
• Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study Cite
  Abdel‐Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo‐Argüelles O, Amir E, et al. Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study. Journal of the American Heart Association. Ovid Technologies (Wolters Kluwer Health); 2021; 10.1161/jaha.119.018393
• The chemosensitizer ferulic acid enhances epirubicin-induced apoptosis in MDA-MB-231 cells Cite
  Cheng W, Zhang P, Luo Q, Deng S, Jia A. The chemosensitizer ferulic acid enhances epirubicin-induced apoptosis in MDA-MB-231 cells. Journal of Functional Foods. Elsevier BV; 2020; 73:104130 10.1016/j.jff.2020.104130
• Exercise Intolerance in Anthracycline‐Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition Cite
  Beaudry RI, Kirkham AA, Thompson RB, Grenier JG, Mackey JR, Haykowsky MJ. Exercise Intolerance in Anthracycline‐Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition. The Oncologist. Wiley; 2020; 25 10.1634/theoncologist.2019-0777
• Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study Cite
  Kaboré EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLOS Medicine. Public Library of Science (PLoS); 2019; 16:e1002989 10.1371/journal.pmed.1002989
• Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study Cite
  Cerulla N, Arcusa À, Navarro J, Garolera M, Enero C, Chico G, et al. Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 164:179-187 10.1007/s10549-017-4240-6
• Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy Cite
  de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, et al. Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. European Journal of Cancer. Elsevier BV; 2015; 51:2517-2524 10.1016/j.ejca.2015.08.011
• Surgery for widely disseminated breast cancer: prolonged control by excision of metastases Cite
  Rees GJ, Britton DC, Malcolm GP, Rees M. Surgery for widely disseminated breast cancer: prolonged control by excision of metastases. JRSM Short Reports. SAGE Publications; 2012; 3:1-4 10.1258/shorts.2012.011162
• Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity Cite
  El-Demerdash E, Ali AA, El-Taher DE, Hamada FM. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity. Journal of Pharmacy and Pharmacology. Wiley; 2011; 64:344-352 10.1111/j.2042-7158.2011.01413.x
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Cite
  Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. Elsevier BV; 2012; 379:432-444 10.1016/s0140-6736(11)61625-5
• Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer Cite
  Han Y, Yu Z, Wen S, Zhang B, Cao X, Wang X. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:483-490 10.1007/s10549-011-1799-1
• Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Cite
  Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. Wiley; 2011; 118:2385-2393 10.1002/cncr.26555
• Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Cite
  Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. Wiley; 2011; 13:1-10 10.1093/eurjhf/hfq213
• Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer Cite
  Winter M, Syddall S, Cross S, Evans A, Ingram C, Jolley I, et al. Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts. American Association for Cancer Research; 2010; 10.1158/0008-5472.sabcs10-p1-11-01
• Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer Cite
  Ishitobi M, Komoike Y, Motomura K, Koyama H, Inaji H. Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer. Oncology. S. Karger AG; 2010; 78:213-219 10.1159/000313702
• Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer Cite
  Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2009; 27:3297-3302 10.1200/jco.2009.19.6410